Gilead Sciences (GILD) Stock Forecast & Price Target

Compare

13,303 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GILD Analyst Ratings

Moderate Buy

15 Buy

6 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Gilead

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

$119.33

▲(7.67%Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $119.33 with a high forecast of $140.00 and a low forecast of $92.00. The average price target represents a 7.67% change from the last price of $110.83.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"60":"$60","141":"$141","80.25":"$80.3","100.5":"$100.5","120.75":"$120.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":119.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$119.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$92.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[60,80.25,100.5,120.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.14,110.59076923076923,113.04153846153847,115.49230769230769,117.94307692307692,120.39384615384616,122.84461538461538,125.29538461538462,127.74615384615385,130.19692307692307,132.6476923076923,135.09846153846155,137.54923076923077,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.14,109.00076923076924,109.86153846153846,110.7223076923077,111.58307692307692,112.44384615384615,113.30461538461539,114.16538461538461,115.02615384615385,115.88692307692308,116.7476923076923,117.60846153846154,118.46923076923076,{"y":119.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.14,106.89846153846153,105.65692307692308,104.41538461538461,103.17384615384616,101.93230769230769,100.69076923076923,99.44923076923077,98.20769230769231,96.96615384615384,95.72461538461539,94.48307692307692,93.24153846153847,{"y":92,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":61.51,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.5,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.53,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.08,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.93,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.84,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$140.00

Average Price Target$119.33

Lowest Price Target$92.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$119

Buy

7.37%

Upside

Reiterated

05/22/25

Gilead Sciences scores well due to its strong financial performance and strategic focus on expanding its product pipeline. The company's efficient cash flow management and profitability provide a solid foundation, despite challenges like stagnant revenue growth and declining sales in certain segments. Technical indicators and valuation metrics further support its stability and fair market valuation, while the recent earnings call underscores promising growth in key areas.

Tim AndersonBank of America Securities

Bank of America Securities

$126

Buy

13.69%

Upside

Reiterated

06/15/25

Gilead Sciences: Strong HIV Market Position and Diversified Growth Strategy Justify Buy Rating

Geoff MeachamCiti

Citi

$125

Buy

12.79%

Upside

Reiterated

06/13/25

Citi sees Gilead clinical holds as only 'minor setback'Citi sees Gilead clinical holds as only 'minor setback'

Michael YeeJefferies

Jefferies

$130

Buy

17.30%

Upside

Reiterated

06/13/25

Optimistic Outlook for Gilead Sciences Driven by Lenacapavir's Market Potential

Salveen RichterGoldman Sachs

Goldman Sachs

$100

Hold

-9.77%

Downside

Reiterated

06/10/25

Gilead Sciences: Balancing Strategic Growth and Clinical Uncertainty with a Hold Rating

Terence FlynnMorgan Stanley

Morgan Stanley

$135

Buy

21.81%

Upside

Reiterated

06/10/25

Gilead Sciences: Buy Rating Affirmed Amid Strategic Positioning and Robust HIV Pipeline

Mohit BansalWells Fargo

Wells Fargo

$140

Buy

26.32%

Upside

Reiterated

06/10/25

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA) and Gilead Sciences (NASDAQ: GILD)

Brian AbrahamsRBC Capital

RBC Capital

$92

Hold

-16.99%

Downside

Reiterated

06/10/25

RBC Capital Remains a Hold on Gilead Sciences (GILD)

Matthew BieglerOppenheimer

Oppenheimer

$125

Buy

12.79%

Upside

Reiterated

06/10/25

Oppenheimer 'not sounding the alarm just yet' on Gilead after clinical holdOppenheimer 'not sounding the alarm just yet' on Gilead after clinical hold

Courtney BreenBernstein

Bernstein

$120

Buy

8.27%

Upside

Reiterated

06/09/25

Bernstein Sticks to Their Buy Rating for Gilead Sciences (GILD)

Tyler Van BurenTD Cowen

TD Cowen

$110

Buy

-0.75%

Downside

Reiterated

06/02/25

TD Cowen Sticks to Its Buy Rating for Gilead Sciences (GILD)

Asthika GoonewardeneTruist Financial

Truist Financial

―

Hold

―

Reiterated

06/02/25

Gilead Sciences (GILD) Gets a Hold from Truist Financial

Daina GrayboschLeerink Partners

Leerink Partners

$115

Buy

3.76%

Upside

Reiterated

06/02/25

Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value

Nico ChenDBS

DBS

$125

Buy

12.79%

Upside

Reiterated

05/30/25

Gilead Sciences: Strong Market Position and Growth Potential Justify Buy Rating

Joseph StringerNeedham

Needham

―

Hold

―

Reiterated

05/21/25

Needham Sticks to Their Hold Rating for Gilead Sciences (GILD)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$119

Buy

7.37%

Upside

Reiterated

05/22/25

Tim AndersonBank of America Securities

Bank of America Securities

$126

Buy

13.69%

Upside

Reiterated

06/15/25

Gilead Sciences: Strong HIV Market Position and Diversified Growth Strategy Justify Buy Rating

Geoff MeachamCiti

Citi

$125

Buy

12.79%

Upside

Reiterated

06/13/25

Citi sees Gilead clinical holds as only 'minor setback'Citi sees Gilead clinical holds as only 'minor setback'

Michael YeeJefferies

Jefferies

$130

Buy

17.30%

Upside

Reiterated

06/13/25

Optimistic Outlook for Gilead Sciences Driven by Lenacapavir's Market Potential

Salveen RichterGoldman Sachs

Goldman Sachs

$100

Hold

-9.77%

Downside

Reiterated

06/10/25

Gilead Sciences: Balancing Strategic Growth and Clinical Uncertainty with a Hold Rating

Terence FlynnMorgan Stanley

Morgan Stanley

$135

Buy

21.81%

Upside

Reiterated

06/10/25

Gilead Sciences: Buy Rating Affirmed Amid Strategic Positioning and Robust HIV Pipeline

Mohit BansalWells Fargo

Wells Fargo

$140

Buy

26.32%

Upside

Reiterated

06/10/25

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA) and Gilead Sciences (NASDAQ: GILD)

Brian AbrahamsRBC Capital

RBC Capital

$92

Hold

-16.99%

Downside

Reiterated

06/10/25

RBC Capital Remains a Hold on Gilead Sciences (GILD)

Matthew BieglerOppenheimer

Oppenheimer

$125

Buy

12.79%

Upside

Reiterated

06/10/25

Oppenheimer 'not sounding the alarm just yet' on Gilead after clinical holdOppenheimer 'not sounding the alarm just yet' on Gilead after clinical hold

Courtney BreenBernstein

Bernstein

$120

Buy

8.27%

Upside

Reiterated

06/09/25

Bernstein Sticks to Their Buy Rating for Gilead Sciences (GILD)

Tyler Van BurenTD Cowen

TD Cowen

$110

Buy

-0.75%

Downside

Reiterated

06/02/25

TD Cowen Sticks to Its Buy Rating for Gilead Sciences (GILD)

Asthika GoonewardeneTruist Financial

Truist Financial

―

Hold

―

Reiterated

06/02/25

Gilead Sciences (GILD) Gets a Hold from Truist Financial

Daina GrayboschLeerink Partners

Leerink Partners

$115

Buy

3.76%

Upside

Reiterated

06/02/25

Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value

Nico ChenDBS

DBS

$125

Buy

12.79%

Upside

Reiterated

05/30/25

Gilead Sciences: Strong Market Position and Growth Potential Justify Buy Rating

Joseph StringerNeedham

Needham

―

Hold

―

Reiterated

05/21/25

Needham Sticks to Their Hold Rating for Gilead Sciences (GILD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

1 Month

xxx

Success Rate

20/30 ratings generated profit

Average Return

+2.94%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.94% per trade.

3 Months

xxx

Success Rate

21/30 ratings generated profit

Average Return

+3.57%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +3.57% per trade.

1 Year

Chris SchottJ.P. Morgan

Success Rate

14/16 ratings generated profit

Average Return

+21.89%

reiterated a buy rating 2 months ago

Copying Chris Schott's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +21.89% per trade.

2 Years

xxx

Success Rate

16/16 ratings generated profit

Average Return

+31.16%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +31.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GILD has received 47 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 119.33.

Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is $1.94 with a range of $1.86 to $2.05. The previous quarter’s EPS was $1.81. GILD beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year GILD has Outperformed its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is $6.96B with a range of $6.74B to $7.27B. The previous quarter’s sales results were $6.65B. GILD beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year GILD has Outperformed its overall industry.

GILD Stock Forecast FAQ

What is GILD’s average 12-month price target, according to analysts?

Based on analyst ratings, Gilead Sciences’s 12-month average price target is 119.33.

What is GILD’s upside potential, based on the analysts’ average price target?

Gilead Sciences has 7.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GILD a Buy, Sell or Hold?

Gilead Sciences has a consensus rating of Moderate Buy which is based on 15 buy ratings, 6 hold ratings and 0 sell ratings.

What is Gilead Sciences’s price target?

The average price target for Gilead Sciences is 119.33. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $92.00. The average price target represents 7.67% Increase from the current price of $110.83.

What do analysts say about Gilead Sciences?

Gilead Sciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of GILD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Gilead Sciences (GILD) Stock Forecast & Price Target

GILD Analyst Ratings

GILD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gilead Sciences

GILD Analyst Recommendation Trends

GILD Financial Forecast

GILD Earnings Forecast

GILD Sales Forecast

GILD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts